Pharmacokinetics of actinomycin 0 in patients with malignant melanoma | Zendy

Tattersall M.H.N. | Zendy; Sodergren J. E. | Zendy; Sengupta S. K. | Zendy; Trites D. H. | Zendy; Modest E. J. | Zendy; Frei Emil , | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Pharmacokinetics of actinomycin 0 in patients with malignant melanoma

Author(s) -

Tattersall M.H.N.,

Sodergren J. E.,

Sengupta S. K.,

Trites D. H.,

Modest E. J.,

Frei Emil ,

Publication year - 1975

Publication title -

clinical pharmacology and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.941

H-Index - 188

eISSN - 1532-6535

pISSN - 0009-9236

DOI - 10.1002/cpt1975176701

Subject(s) - pharmacokinetics , melanoma , medicine , pharmacology , cancer research

The distribution and excretion of tritiated actinomycin D have been determined in 3 adult patients with disseminated malignant melanoma. In the blood, the drug was preferentially taken up into nucleated cells. The urinary and fecal excretion was prolonged and only about 30% of the dose of actinomycin was recovered in 9 days. There was evidence that the drug was concentrated in bone marrow and tumor cells, but did not readily cross the blood‐brain barrier. The long tissue half‐life of actinomycin D suggests that an intermittent schedule of administration would be the most effective.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research